Leber

The Goddard School's Location in New Market, Maryland is Now Open

Retrieved on: 
Tuesday, March 8, 2022
Goddard School, NEW, Sign language, School, Student, Leber, Music, Julius Leber, Curriculum, Program, Social skills, Learning, Parent, Urbana, Education, Child, MD, Accreditation, Wilderness, Toy, Tutoring

More importantly, a targeted curriculum focused on social-emotional development teaches children how to be kind to themselves and to others.

Key Points: 
  • More importantly, a targeted curriculum focused on social-emotional development teaches children how to be kind to themselves and to others.
  • "Goddard is the premier choice for early childhood education, and when the opportunity to open a school presented itself, my husband and I couldn't pass it up."
  • The 11,000-square-foot Goddard School is equipped with nine classrooms to serve 125 infants, toddlers and preschool-aged children.
  • With its official opening, The Goddard School of New Market joins more than 570 franchised locations in 38 states.

Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Leber's hereditary optic neuropathy, Idebenone, Organ systems, Proteins, Nervous system, Optic neuropathy, Leber, Peripheral neuropathy, Mitochondrial optic neuropathies

Pratteln, Switzerland, June 23, 2021 Santhera Pharmaceuticals (SIX: SANN) announces positive topline results from its long-term Phase 4 LEROS study with Raxone (idebenone) in the treatment of Lebers hereditary optic neuropathy (LHON).

Key Points: 
  • Pratteln, Switzerland, June 23, 2021 Santhera Pharmaceuticals (SIX: SANN) announces positive topline results from its long-term Phase 4 LEROS study with Raxone (idebenone) in the treatment of Lebers hereditary optic neuropathy (LHON).
  • The primary endpoint, proportion of eyes with clinically relevant benefit after 12 months treatment with Raxone versus untreated patients from an external control group, was met with high statistical significance (p=0.002).
  • In September 2015, Raxone received the marketing authorization from the European Medicines Agency (EMA) for the treatment of patients with Leber's hereditary optic neuropathy (LHON).
  • Santhera out-licensed rights to its first approved product, Raxone (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.

Santhera Completes Capital Increase for Financing Arrangements

Retrieved on: 
Thursday, May 20, 2021
Antioxidants, Idebenone, Leber's hereditary optic neuropathy, XC2, Optic neuropathy, Leber, Share, Health, Branches of biology

b"Pratteln, Switzerland, May 20, 2021 \xe2\x80\x93 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,562,375 treasury shares.\nOn May\xc2\xa019, 2021, 2,562,375 shares were issued out of the existing authorized capital as treasury shares.

Key Points: 
  • b"Pratteln, Switzerland, May 20, 2021 \xe2\x80\x93 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,562,375 treasury shares.\nOn May\xc2\xa019, 2021, 2,562,375 shares were issued out of the existing authorized capital as treasury shares.
  • Santhera expects to use these shares for purposes of its financing arrangements, including the Senior Unsecured Convertible Bonds due 2024 (SAN21, CH0563348744) issued on May\xc2\xa04, 2021.
  • Santhera out-licensed ex-North American rights to its first approved product, Raxone\xc2\xae (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.
  • For further information, please visit www.santhera.com .\nRaxone\xc2\xae is a trademark of Santhera Pharmaceuticals.\nFor further information please contact:\nThis communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG.

Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024

Retrieved on: 
Tuesday, May 4, 2021
Financial markets, Financial economics, Corporate finance, Stock market, Leber's hereditary optic neuropathy, Prospectus, Idebenone, Convertible bond, Leber, XC2, Security

Santhera out-licensed ex-North American rights to its first approved product, Raxone\xc2\xae (idebenone), for the treatment of Leber\'s hereditary optic neuropathy (LHON) to Chiesi Group.

Key Points: 
  • Santhera out-licensed ex-North American rights to its first approved product, Raxone\xc2\xae (idebenone), for the treatment of Leber\'s hereditary optic neuropathy (LHON) to Chiesi Group.
  • It is not intended to extend the Exchange Offer to any such country or jurisdiction.
  • Information distributed in connection with the Exchange Offer is subject to Swiss disclosure requirements that are different from those of the United States.
  • Investors should make their decision to accept the Exchange Offer solely based on the Notice of a Repurchase Offer (Exchange of CHF\xc2\xa060,000,000 Senior Unsecured Convertible Bonds due 2022) and the preliminary offering and listing prospectus regarding the New Bonds, each dated March\xc2\xa025, 2021 which, subject to compliance with applicable securities laws, is accessible via https://www.santhera.com/investors-and-media/investor-toolbox/bond-excha... .

Santhera Completes Capital Increases for Financing Arrangements

Retrieved on: 
Friday, April 30, 2021
Antioxidants, Idebenone, Leber's hereditary optic neuropathy, Branches of biology, Optic neuropathy, Leber, XC2, Share, Health

At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares.

Key Points: 
  • At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares.
  • The newly created registered shares will initially be held as treasury shares in order to fulfill obligations arising from Santhera's financing instruments.
  • After the capital increases, Santhera's share capital amounts to 26,201,136 shares.\nThe new shares will be listed as per May\xc2\xa03, 2021.\nSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.
  • Santhera out-licensed ex-North American rights to its first approved product, Raxone\xc2\xae (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.

ProQR Announces Annual Meeting of Shareholders

Retrieved on: 
Tuesday, April 20, 2021
ProQR, Retinitis pigmentosa, Leber

b'LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the Annual General Meeting of Shareholders will take place on Wednesday, May 19, 2021 at 16:00 CET (10:00am EDT) via videoconference.\nAll relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the \xe2\x80\x9cInvestors & Media\xe2\x80\x9d section of ProQR\xe2\x80\x99s website ( www.proqr.com ) under \xe2\x80\x9cFinancial Information\xe2\x80\x9d.

Key Points: 
  • b'LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the Annual General Meeting of Shareholders will take place on Wednesday, May 19, 2021 at 16:00 CET (10:00am EDT) via videoconference.\nAll relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the \xe2\x80\x9cInvestors & Media\xe2\x80\x9d section of ProQR\xe2\x80\x99s website ( www.proqr.com ) under \xe2\x80\x9cFinancial Information\xe2\x80\x9d.
  • The documents will also be made available on the SEC\xe2\x80\x99s website at www.sec.gov .
  • Shareholders that wish to attend the videoconference should register as described in the notice and agenda, after which they will receive login details for the videoconference.\nProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa.
  • Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.\nLearn more about ProQR at www.proqr.com.\n'

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Retrieved on: 
Friday, April 2, 2021
Ophthalmology, Medical specialties, ProQR, Organ systems, Leber congenital amaurosis, Visual impairment, Leber, Pediatric ophthalmology, Amaurosis, LCA, American Association for Pediatric Ophthalmology and Strabismus, Strabismus

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.

Key Points: 
  • LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.
  • The presentation will be available for viewing until July 15, 2021.
  • Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children.
  • It consists of a group of diseases of which LCA10 is the most frequent and one of the most severe forms.

Santhera Completes Capital Increase for Financing Arrangements

Retrieved on: 
Tuesday, March 30, 2021
Branches of biology, Proteins, Leber's hereditary optic neuropathy, Idebenone, Optic neuropathy, Leber, Share

On March29, 2021, 2,200,000 shares were issued out of the existing authorized capital as treasury shares.

Key Points: 
  • On March29, 2021, 2,200,000 shares were issued out of the existing authorized capital as treasury shares.
  • Santhera expects to use these shares for purposes of its financing arrangements.
  • Santhera out-licensed ex-North American rights to its first approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.
  • For further information please contact:
    This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG.

Santhera Completes Capital Increase for Financing Arrangements

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Leber's hereditary optic neuropathy, Idebenone, Financial economics, Stock market, Finance, Optic neuropathy, Leber, Share, Treasury stock

Pratteln, Switzerland, March10, 2021 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares.

Key Points: 
  • Pratteln, Switzerland, March10, 2021 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares.
  • On March9, 2021, and as announced when calling the extraordinary general meeting of shareholders scheduled for March18, 2021, 480,708 shares were issued out of the existing authorized capital as treasury shares.
  • Santhera expects to use these shares for purposes of its financing arrangements.
  • Santhera out-licensed ex-North American rights to its first approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Biology, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Leber congenital amaurosis, Retina, Gene therapy, Amaurosis, Leber, Photoreceptor cell-specific nuclear receptor

We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases (IRDs).

Key Points: 
  • We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases (IRDs).
  • Nuclear Hormone Receptors such as NR2E3 are important modulators of retinal development and function acting as master genes in the retina.
  • Leber congenital amaurosis is a family of congenital retinal dystrophies that results in severe vision loss at an early age.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.